|
|
术前MRI特征预测高强度聚焦超声治疗晚期胰腺癌的近期疗效
|
Abstract:
目的：探讨术前动态增强MRI影像学特征在预测高强度聚焦超声(High-intensity focused ultrasound, HIFU)治疗晚期胰腺癌(Advanced pancreatic cancer, APC)近期疗效中的应用价值。方法：回顾性分析2019年7月至2021年5月于我院行HIFU治疗的53例APC患者的临床及影像学资料，采用Logistic回归分析探究不良预后的相关危险因素，以受试者工作特征曲线(ROC)评价其预测效能。结果：53例APC患者有效率为22.6%，局部控制率为64.2%。Logistic回归分析结果显示肿瘤大小(P = 0.008)及边缘强化(P = 0.040)是预测APC患者HIFU术后短期不良预后的独立性危险因素；ROC曲线分析显示当肿瘤大小取截断值3.45 cm时，预测效能最高。结论：术前动态增强MRI显示的肿瘤大小及边缘强化对APC患者HIFU术后的近期疗效具有较高的预测价值。
Objective: To investigate the application value of preoperative dynamic enhanced MRI imaging features in predicting the short-term efficacy of High-intensity focused ultrasound (HIFU) in the treatment of advanced pancreatic cancer. Methods: The clinical and imaging data of 53 APC patients treated with HIFU in our hospital from July 2019 to May 2021 were collected. Logistic regression analysis was used to explore the related risk factors of poor prognosis, and the receiver operating characteristic curve (ROC) was used to evaluate the predictive efficacy. Results: The effective rate of 53 APC patients was 22.6%, and the local control rate was 64.2%. Logistic regression analysis showed that tumor size (P = 0.008) and edge enhancement (P = 0.040) were independent risk fac-tors for short-term poor prognosis after HIFU in APC patients. ROC curve analysis showed that when the tumor size was cut off at 3.45 cm, the predictive sensitivity was the highest. Conclusion: The tu-mor size and edge enhancement displayed by preoperative dynamic enhanced MRI have high pre-dictive value for the short-term efficacy of APC patients after HIFU.
| [1] | Springfeld, C., J？ger, D., Büchler, M.W., et al. (2019) Chemotherapy for Pancreatic Cancer. Presse Medicale (Paris, France: 1983), 48, e159-e174. https://doi.org/10.1016/j.lpm.2019.02.025 |
| [2] | 高强度聚焦超声肿瘤治疗系统临床应用指南(试行) [J]. 中华医学杂志, 2005(12): 796-797. |
| [3] | Marinova, M., Wilhelm-Buchstab, T. and Strunk, H. (2019) Advanced Pancreatic Cancer: High-Intensity Focused Ultrasound (HIFU) and Other Local Ablative Therapies. RoFo: Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin, 191, 216-227. https://doi.org/10.1055/a-0820-5564 |
| [4] | Yousaf, T., Dervenoulas, G. and Politis, M. (2018) Advances in MRI Methodology. International Review of Neurobiology, 141, 31-76. https://doi.org/10.1016/bs.irn.2018.08.008 |
| [5] | 杨欢, 王晓坤, 范金虎. 中国胰腺癌流行病学、危险因素及筛查现况[J]. 肿瘤防治研究, 2021, 48(10): 909-915. |
| [6] | 颜晓一, 谭莉, 吕珂. 经腹超声在介入治疗局部进展期胰腺癌中的应用[J]. 中国介入影像与治疗学, 2021, 18(9): 558-561. |
| [7] | Tao, S.F., Gu, W.H., Gu, J.C., et al. (2019) A Retrospective Case Series of High-Intensity Focused Ultrasound (HIFU) in Combination with Gemcitabine and Oxaliplatin (Gemox) on Treating El-derly Middle and Advanced Pancreatic Cancer. OncoTargets and Therapy, 12, 9735-9745. https://doi.org/10.2147/OTT.S220299 |
| [8] | 祝宝让, 刁立岩, 李静, 等. 进展期胰腺癌的高强度聚焦超声消融治疗[J]. 中国超声医学杂志, 2019, 35(9): 817-820. |
| [9] | Zhu, B., Li, J., Diao, L., et al. (2019) High-Intensity Focused Ultrasound Ablation for Advanced Pancreatic Cancer. Journal of Cancer Research and Therapeutics, 15, 831-835. https://doi.org/10.4103/jcrt.JCRT_408_18 |
| [10] | Zhou, Y. (2014) High-Intensity Focused Ultrasound Treatment for Advanced Pancreatic Cancer. Gastroenterology Research and Practice, 2014, Article ID: 205325. https://doi.org/10.1155/2014/205325 |
| [11] | Marchegiani, G. andrianello, S., Malleo, G., et al. (2017) Does Size Matter in Pancreatic Cancer? Reappraisal of Tumour Dimension as a Predictor of Outcome beyond the TNM. Annals of Surgery, 266, 142-148.
https://doi.org/10.1097/SLA.0000000000001837 |
| [12] | Egawa, S., Toma, H., Ohigashi, H., et al. (2012) Japan Pan-creatic Cancer Registry; 30th Year Anniversary: Japan Pancreas Society. Pancreas, 41, 985-992. https://doi.org/10.1097/MPA.0b013e318258055c |
| [13] | Lim, J.E., Chien, M.W. and Earle, C.C. (2003) Prognostic Factors Following Curative Resection for Pancreatic Adenocarcinoma: A Population-Based, Linked Database Analysis of 396 Patients. Annals of Surgery, 237, 74-85.
https://doi.org/10.1097/00000658-200301000-00011 |
| [14] | Mitsunaga, S., Hasebe, T., Iwasaki, M., et al. (2005) Important Prognostic Histological Parameters for Patients with Invasive Ductal Carcinoma of the Pancreas. Cancer Sci-ence, 96, 858-865.
https://doi.org/10.1111/j.1349-7006.2005.00128.x |
| [15] | Lee, S., Kim, S.H., Park, H.K., et al. (2018) Pancreatic Ductal Adenocarcinoma: Rim Enhancement at MR Imaging Predicts Prognosis after Curative Resection. Radiology, 288, 456-466. https://doi.org/10.1148/radiol.2018172331 |
| [16] | Hattori, Y., Gabata, T., Zen, Y., et al. (2010) Poorly En-hanced Areas of Pancreatic Adenocarcinomas on Late-Phase Dynamic Computed Tomography: Comparison with Patho-logical Findings. Pancreas, 39, 1263-1270.
https://doi.org/10.1097/MPA.0b013e3181dbc583 |
| [17] | Kuhlmann, K.F., De Castro, S.M., Wesseling, J.G., et al. (2004) Surgical Treatment of Pancreatic Adenocarcinoma; Actual Survival and Prognostic Factors in 343 Patients. Euro-pean Journal of Cancer (Oxford, England: 1990), 40, 549-558. https://doi.org/10.1016/j.ejca.2003.10.026 |
| [18] | Lüttges, J., Schemm, S., Vogel, I., et al. (2000) The Grade of Pan-creatic Ductal Carcinoma Is an Independent Prognostic Factor and Is Superior to the Immunohistochemical Assessment of Proliferation. The Journal of Pathology, 191, 154-161. https://doi.org/10.1002/(SICI)1096-9896(200006)191:2<154::AID-PATH603>3.0.CO;2-C |
| [19] | Rochefort, M.M., Ankeny, J.S., Kadera, B.E., et al. (2013) Impact of Tumor Grade on Pancreatic Cancer Prognosis: Validation of a Novel TNMG Staging System. Annals of Surgical Oncology, 20, 4322-4329.
https://doi.org/10.1245/s10434-013-3159-3 |
| [20] | Kim, J.H., Park, S.H., Yu, E.S., Kim, M.H., et al. (2010) Visually Isoattenuating Pancreatic Adenocarcinoma at Dynamic-Enhanced CT: Frequency, Clinical and Pathologic Characteristics, and Diagnosis at Imaging Examinations. Radiology, 257, 87-96. https://doi.org/10.1148/radiol.10100015 |
